Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company developing azetukalner and other ion channel modulators for epilepsy, major depressive disorder (MDD), bipolar depression (BPD), and pain. As a foreign private issuer incorporated in Canada and listed on The Nasdaq Global Market, Xenon uses SEC reports to disclose financial results, executive changes, and other material events.
Among the key documents available here are Form 8-K filings, which Xenon uses to report quarterly financial results, business updates, and corporate developments such as the appointment of its Chief Financial Officer and related employment and equity arrangements. These filings often reference the company’s Phase 3 clinical programs in focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), MDD, and BPD, as well as its early-stage NaV1.7, Kv7, and NaV1.1 programs.
Investors can also review exhibits attached to 8-Ks, including press releases that summarize results of operations and financial condition, R&D spending, and cash runway expectations, along with risk-focused forward-looking statements. Additional filings detail governance and compensation matters, such as severance protections and equity inducement grants made under Xenon’s inducement equity incentive plans.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, explain technical language, and help users quickly identify information about Xenon’s clinical pipeline, executive changes, and financial disclosures. Users can also locate information relevant to insider and equity-related activity through option and restricted share unit grant disclosures contained in the company’s current reports.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported a combination of option exercises, performance share vesting and share sales. He exercised stock options covering 290,000 Common Shares at exercise prices between $3.10 and $9.44 per share, and a 20,000-unit performance share award vested based on milestone achievement.
Across multiple open-market transactions, he sold a total of 281,269 Common Shares at weighted-average prices generally between the high-$50s and low-$60s. Footnotes state these sales were made under Rule 10b5‑1 trading arrangements, including a durable sell-to-cover instruction adopted solely to satisfy tax withholding on the vested performance share units. After these transactions, he holds 14,731 Common Shares directly and 14,300 Common Shares indirectly through his spouse.
Xenon Pharmaceuticals is offering 10,526,317 common shares and, in lieu of shares to certain investors, 877,194 pre-funded warrants via a prospectus supplement under its shelf registration. The offering price is
The prospectus supplement notes the pre-funded warrants have an exercise price of
XENE filed a Form 144 to sell 20,000 common shares tied to a performance share unit award that vested on
The filing lists prior proposed or completed sales by Ian Mortimer of 40,000 shares on
Xenon Pharmaceuticals Inc. is offering
XENE files a Form 144 reporting the proposed sale of 270,000 common shares through the exercise of options on
Xenon Pharmaceuticals reported positive Phase 3 results from its X-TOLE2 study of azetukalner in adults with focal onset seizures. The trial met its primary endpoint, with median percent change in monthly seizure frequency of -53.2% for the 25 mg dose and -34.5% for 15 mg, versus -10.4% for placebo, giving a placebo-adjusted effect of -42.7% for 25 mg. Key secondary goals were also achieved, including responder rates (≥50% seizure reduction) of 54.8% for 25 mg and 37.6% for 15 mg, versus 20.8% for placebo. Safety and tolerability were generally consistent with prior studies, though dizziness and other nervous system side effects were more frequent at higher doses. Xenon plans to submit a New Drug Application to the FDA for focal onset seizures in the third quarter of 2026 and is preparing for potential commercialization.
Xenon Pharmaceuticals Inc. filed a prospectus supplement to register $400,000,000 of common shares for issuance under its at-the-market equity offering sales agreement with Jefferies and Stifel. This keeps the company’s ATM capacity available for future issuances under an existing sales framework.
The new prospectus supplement replaces and supersedes a prior prospectus, and the earlier offering has been terminated. As of the filing date, the company had already sold $291,084,564 in common shares under the sales agreement pursuant to the prior prospectus.
Xenon Pharmaceuticals Inc. is filing a prospectus supplement to offer
The prospectus supplement replaces a prior prospectus and states that